Investigational drug is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-07. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
===== Macroscopic viscous flow ===== Macroscopic viscous flow fields can direct self-assembly of a random solution of particles into ordered crystals via the shear-assisted nucleation mechanism. However, the flow-induced self-assembly often occurs far from thermodynamic equilibrium and leads to amorphous aggregates of nanoparticles through a mechanism by which the shear flow field overcomes the repulsive energy barrier which stabilizes the nanoparticles against self-assembly in the absence of flow. The assembled particles aggregates tend to disassemble due to flow-induced breakup or when the flow is stopped or removed if the interparticle bonds are weak. Shear flows are also useful for jammed suspensions or random close packing. As these systems begin in nonequilibrium conditions, flow fields are useful in that they help the system relax towards a more ordered equilibrium. Flow fields are also useful when dealing with complex matrices that themselves exhibit rheological behavior. Flow can induce anisotropic viseoelastic stresses, which helps to overcome the matrix and cause self-assembly.
== Other activities == LL-37 plays a role in the activation of cell proliferation and migration, contributing to the wound closure process. All these mechanisms together play an essential role in tissue homeostasis and regenerative processes. Moreover, it has an agonistic effect on various pleiotropic receptors, for example, formyl peptide receptor like-1 (FPRL-1), purinergic receptor P2X7, epidermal growth factor receptor (EGFR). Furthermore, it induces angiogenesis and regulates apoptosis.
integral membrane protein (IMP) Also intrinsic membrane protein. Any of a class of membrane proteins which are permanently embedded within or attached to the cell membrane (as opposed to those which are attached only temporarily). Integral membrane proteins can be subclassified into integral polytopic proteins, which span the entirety of the membrane, and integral monotopic proteins, which adhere only to one side.
== Structures == Both classes of aminoacyl-tRNA synthetases are multidomain proteins. In a typical scenario, an aaRS consists of a catalytic domain (where both the above reactions take place) and an anticodon binding domain (which interacts mostly with the anticodon region of the tRNA). Transfer-RNAs for different amino acids differ not only in their anticodon but also at other points, giving them slightly different overall configurations. The aminoacyl-tRNA synthetases recognize the correct tRNAs primarily through their overall configuration, not just through their anticodon. In addition, some aaRSs have additional RNA binding domains and editing domains that cleave incorrectly paired aminoacyl-tRNA molecules. The catalytic domains of all the aaRSs of a given class are found to be homologous to one another, whereas class I and class II aaRSs are unrelated to one another. The class I aaRSs feature a cytidylyltransferase-like Rossmann fold seen in proteins like glycerol-3-phosphate cytidylyltransferase, nicotinamide nucleotide adenylyltransferase and archaeal FAD synthase, whereas the class II aaRSs have a unique fold related to biotin and lipoate ligases. The alpha helical anticodon binding domain of arginyl-, glycyl- and cysteinyl-tRNA synthetases is known as the DALR domain after characteristic conserved amino acids. Aminoacyl-tRNA synthetases have been kinetically studied, showing that Mg2+ ions play an active catalytic role and therefore aaRs have a degree of magnesium dependence.
Sources: en.wikipedia.org
The cause of Fukuyama congenital muscular dystrophy is rooted in the FKTN gene, located at human chromosome 9q31, encoding the protein fukutin. Mutations in this gene, and therefore the fukutin protein, are the cause of FCMD. The disease is inherited in an autosomal recessive manner. This means the defective gene responsible for the disorder is located on an autosome (chromosome 9 is an autosome), and two copies of the defective gene (one inherited from each parent) are required in order to be born with the disorder. The parents of an individual with an autosomal recessive disorder both carry one copy of the defective gene but usually do not experience any signs or symptoms of the disorder. Two mutations have been identified. The first and most common is an SVA retrotransposal insertion in the 3'-untranslated region. The second is a deep-intronic point mutation c.647+2084G>T. This second mutation has only been found to date in the presence of the first mutation.
Direct testing of bioarchaeological methods for sexing skeletons by comparing gendered names on coffin plates from the crypt at Christ Church, Spitalfields, London to the associated remains achieved a 98 percent success rate. Gendered work patterns may leave marks on bones and be identifiable in the archaeological record. One study found extremely arthritic big toes, a collapse of the last dorsal vertebrae, and muscular arms and legs among female skeletons at Abu Hureyra, interpreting this as indicative of gendered work patterns. Such skeletal changes could have resulted from women spending long periods kneeling while grinding grain with the toes curled forward. Investigation of gender from mortuary remains is of growing interest to archaeologists.
=== Bjerknes feedback === The close relationship between ocean temperatures and the strength of the trade winds was first identified by Jacob Bjerknes in 1969. Bjerknes also hypothesized that ENSO was a positive feedback system where the associated changes in one component of the climate system (the ocean or atmosphere) tend to reinforce changes in the other. This process is known as Bjerknes feedback. For example, during the growth of El Niño, the reduced contrast in ocean temperatures across the Pacific results in weaker trade winds, further reinforcing the El Niño state. Although these associated changes in the ocean and atmosphere often occur together, the state of the atmosphere may resemble a different ENSO phase than the state of the ocean or vice versa. Because their states are closely linked, the variations of ENSO may arise from changes in both the ocean and atmosphere and not necessarily from an initial change of exclusively one or the other. Conceptual models explaining how ENSO operates generally accept the Bjerknes feedback hypothesis. However, ENSO would perpetually remain in one phase if Bjerknes feedback were the only process occurring. Several theories have been proposed to explain how ENSO can change from one state to the next despite the positive feedback. These explanations broadly fall under two categories. In one view, the Bjerknes feedback naturally triggers negative feedbacks that end and reverse the abnormal state of the tropical Pacific.
== Nomenclature == Metastable isomers of a particular isotope are usually designated with an "m". This designation is placed after the mass number of the atom. For example, cobalt-58m1, or 58m127Co, is an isomer of cobalt-58. Here, 27 is the atomic number of cobalt, 58 is the total number of nucleons (meaning it has 31 neutrons), "m" means it is an isomer, and "m1" means it is the first (lowest above the ground state) metastable isomer. For isotopes with more than one metastable isomer, "indices" are placed after the designation, and the labeling becomes m1, m2, m3, and so on. Increasing indices, m1, m2, etc., correlate with increasing levels of excitation energy stored in each of the isomeric states (e.g., hafnium-178m2, or 178m272Hf). The index may be omitted if only one isomer is relevant in-context. For fission isomers, use "f" rather than "m".
Emicerfont (GW-876,008) is a drug developed by GlaxoSmithKline which acts as a CRF-1 antagonist. Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress, and activates the two corticotropin-releasing hormone receptors: CRF1 and CRF2. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress. Emicerfont blocks the CRF1 receptor, and so reduces ACTH release. It has been investigated for the treatment of irritable bowel syndrome (IBS) and alcoholism, and while it was not effective enough to be adopted for medical use in these applications, it continues to be used for research, as the role of the CRH-ACTH system in IBS remains poorly understood.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.